About pyc therapeutics ltd - PYCXF
PYC Therapeutics Ltd. is a drug-development company, which provides a new generation of RNA therapeutics to meet unmet need in disease. It develops intracellular biological therapeutics including its own preclinical oncology payloads, using its proprietary cell Functional Penetrating Phylomers. The company was founded by Richmond Miles Hopkins and Paul Michael Watt on October 9, 2001, and is headquartered in Nedlands, Australia.
PYCXF At a Glance
PYC Therapeutics Ltd.
Harry Perkins Institute
Nedlands, Western Australia (WA) 6009
| Phone | 61-8-6151-0992 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -32,578,869.03 | |
| Sector | Health Technology | Employees | N/A | |
| Fiscal Year-end | 06 / 2026 | |||
| View SEC Filings |
PYCXF Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 4.454 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -6.717 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.002 |
PYCXF Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
PYCXF Liquidity
| Current Ratio | 14.413 |
| Quick Ratio | 14.413 |
| Cash Ratio | 12.426 |
PYCXF Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -35.99 |
| Return on Equity | -39.516 |
| Return on Total Capital | -29.14 |
| Return on Invested Capital | -39.291 |
PYCXF Capital Structure
| Total Debt to Total Equity | 0.604 |
| Total Debt to Total Capital | 0.60 |
| Total Debt to Total Assets | 0.559 |
| Long-Term Debt to Equity | 0.369 |
| Long-Term Debt to Total Capital | 0.366 |